Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
Public ClinicalTrials.gov record NCT01999673. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer
Study identification
- NCT ID
- NCT01999673
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Peregrine Pharmaceuticals
- Industry
- Enrollment
- 582 participants
Conditions and interventions
Conditions
Interventions
- bavituximab Biological
- Docetaxel Drug
- Placebo (for bavituximab) Other
Biological · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2013
- Primary completion
- Feb 28, 2017
- Completion
- Feb 28, 2017
- Last update posted
- Apr 20, 2017
2013 – 2017
United States locations
- U.S. sites
- 39
- U.S. states
- 20
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Peregrine Pharmaceuticals Investigational Site | Huntsville | Alabama | 35805 | — |
| Peregrine Pharmaceuticals Investigational Site | Chandler | Arizona | 85224 | — |
| Peregrine Pharmaceuticals Investigational Site | Glendale | Arizona | 85306 | — |
| Peregrine Pharmaceuticals Investigational Site | Greenbrae | California | 94904 | — |
| Peregrine Pharmaceuticals Investigational Site | Los Angeles | California | 90048 | — |
| Peregrine Pharmaceuticals Investigational Site | Oceanside | California | 92056 | — |
| Peregrine Pharmaceuticals Investigational Site | Orange | California | 92868 | — |
| Peregrine Pharmaceuticals Investigational Site | West Hills | California | 91307 | — |
| Peregrine Pharmaceuticals Investigational Site | Fort Myers | Florida | 33916 | — |
| Peregrine Pharmaceuticals Investigational Site | St. Petersburg | Florida | 33705 | — |
| Peregrine Pharmaceuticals Investigational Site | Tampa | Florida | 33612 | — |
| Peregrine Pharmaceuticals Investigational Site | Athens | Georgia | 30607 | — |
| Peregrine Pharmaceuticals Investigational Site | Savannah | Georgia | 31404 | — |
| Peregrine Pharmaceuticals Investigational Site | Chicago | Illinois | 60637 | — |
| Peregrine Pharmaceuticals Investigational Site | Indianapolis | Indiana | 46254 | — |
| Peregrine Pharmaceuticals Investigational Site | Marrero | Louisiana | 70006 | — |
| Peregrine Pharmaceuticals Investigational Site | Shreveport | Louisiana | 71101 | — |
| Peregrine Pharmaceuticals Investigational Site | Baltimore | Maryland | 21201 | — |
| Peregrine Pharmaceuticals Investigational Site | Frederick | Maryland | 21701 | — |
| Peregrine Pharmaceuticals Investigational Site | Boston | Massachusetts | 02114 | — |
| Peregrine Pharmaceuticals Investigational Site | Lincoln | Nebraska | 68506 | — |
| Peregrine Pharmaceuticals Investigational Site | Lebanon | New Hampshire | 03756 | — |
| Peregrine Pharmaceuticals Investigational Site | Albuquerque | New Mexico | 87131 | — |
| Peregrine Pharmaceuticals Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| Peregrine Pharmaceuticals Investigational Site | Cincinnati | Ohio | 45242 | — |
| Peregrine Pharmaceuticals Investigational Site | Middletown | Ohio | 45042 | — |
| Peregrine Pharmaceuticals Investigational Site | Portland | Oregon | 97213 | — |
| Peregrine Pharmaceuticals Investigational Site | Hershey | Pennsylvania | 17033 | — |
| Peregrine Pharmaceuticals Investigational Site | Pittsburgh | Pennsylvania | 15232 | — |
| Peregrine Pharmaceuticals Investigational Site | Chattanooga | Tennessee | 37404 | — |
| Peregrine Pharmaceuticals Investigational Site | Knoxville | Tennessee | 37909 | — |
| Peregrine Pharmaceuticals Investigational Site | Nashville | Tennessee | 37203 | — |
| Peregrine Pharmaceuticals Investigational Site | Nashville | Tennessee | 37323 | — |
| Peregrine Pharmaceuticals Investigational Site | Abilene | Texas | 79606 | — |
| Peregrine Pharmaceuticals Investigational Site | Dallas | Texas | 75201 | — |
| Peregrine Pharmaceuticals Investigational Site | Dallas | Texas | 75390 | — |
| Peregrine Pharmaceuticals Investigational Site | Fort Worth | Texas | 76104 | — |
| Peregrine Pharmaceuticals Investigational Site | Temple | Texas | 76508 | — |
| Peregrine Pharmaceuticals Investigational Site | Seattle | Washington | 98108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 122 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01999673, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2017 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01999673 live on ClinicalTrials.gov.